The association of PPARGC1B (a PPARγ coactivator) with favorable prognosis suggests that enhancing lipid catabolism may counteract tumor growth, whereas PFKFB4-mediated pentose phosphate flux promotes lipogenesis, driving aggressiveness [66]. Here, PFKFB4 is linked to neoplasm.